Sonic Hedgehog Pathway Inhibition in the Treatment of Advanced Basal Cell Carcinoma

Area of Science:

• Oncology
• Dermatology
• Molecular Biology

Background:

• Advanced basal cell carcinoma (BCC) presents challenges due to limited treatment efficacy and high recurrence rates.
• The Sonic hedgehog (Shh) pathway is implicated in BCC development, leading to targeted therapies.
• Current treatments for advanced BCC include two FDA-approved Shh inhibitors: vismodegib and sonidegib.

Purpose of the Study:

• To review the current landscape of Shh pathway inhibitors for advanced BCC.
• To discuss the efficacy, limitations, and side effect management of approved Shh inhibitors.
• To explore emerging roles and future directions for Shh inhibitors in BCC treatment.

Main Methods:

• Review of current literature on Shh pathway inhibitors in advanced BCC.
• Analysis of FDA-approved agents (vismodegib, sonidegib) and their indications.
• Discussion of adverse events and management strategies.
• Exploration of off-label uses and investigational agents.

Main Results:

• Vismodegib and sonidegib are approved for advanced BCC, with specific indications for locally advanced and metastatic disease.
• Shh inhibitors are being explored for nevoid basal cell carcinoma syndrome prevention and neoadjuvant therapy.
• Common adverse events include muscle spasms, alopecia, dysgeusia, nausea, and weight loss, often necessitating treatment discontinuation.
• Head-to-head trials comparing vismodegib and sonidegib are lacking.
• Investigational agents and alternative Shh inhibitors like itraconazole show potential but require further research.

Conclusions:

• Shh pathway inhibitors have significantly improved treatment outcomes for advanced BCC.
• Effective management of adverse events is critical for sustained patient benefit.
• Further research is needed to optimize the use of Shh inhibitors and explore novel therapeutic strategies for resistant BCC.
• The role of Shh inhibitors in BCC prevention and neoadjuvant settings is expanding.